{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:58:51Z","timestamp":1783349931554,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-020-040"],"award-info":[{"award-number":["BCRF-020-040"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In clinical practice, oestrogen receptor (ER) analysis is almost entirely by immunohistochemistry (IHC). ASCO\/CAP recommends cut-offs of\u2009&lt;\u20091% (negative) and 1\u201310% (low) cells positive. There is uncertainty whether patients with ER low tumours benefit from endocrine therapy. We aimed to assess IHC and mRNA cut-points for ER versus biological response of primary breast cancer to 2\u00a0weeks\u2019 aromatase inhibitor treatment as measured by change in Ki67.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cases were selected from the aromatase inhibitor treatment group of POETIC. We selected the 15% with the poorest Ki67 response (PR,\u2009&lt;\u200940% Ki67 suppression, <jats:italic>n<\/jats:italic>\u2009=\u2009230) and a random 30% of the remainder categorised as intermediate (IR, 40\u201379% Ki67 suppression, <jats:italic>n<\/jats:italic>\u2009=\u2009150) and good-responders (GR,\u2009\u2265\u200980% Ki67 suppression, <jats:italic>n<\/jats:italic>\u2009=\u2009230) from HER2\u2009\u2212 group. All HER2\u2009+\u2009cases available were selected irrespective of their response category (<jats:italic>n<\/jats:italic>\u2009=\u2009317). ER expression was measured by IHC and qPCR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ER IHC was available from 515 HER2\u2009\u2212 and 186 HER2\u2009+\u2009tumours and ER qPCR from 367 HER2\u2009\u2212 and 171 HER2\u2009+\u2009tumours. Ninety-one percentage of patients with ER IHC\u2009&lt;\u200910% were PRs with similar rates in HER2\u2009\u2212 and HER2\u2009+\u2009cases. At or above ER IHC 10% substantial numbers of patients showed IR or GR. Similar proportions of patients were defined by cut-points of ER IHC\u2009&lt;\u200910% and ER mRNA\u2009&lt;\u20095 units. In addition, loss of PgR expression altered ER anti-proliferation response with 92% of PgR\u2009\u2212 cases with ER IHC\u2009&lt;\u200940% being PRs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>There was little responsiveness at IHC\u2009&lt;\u200910% and no distinction between\u2009&lt;\u20091% and 1\u201310% cells positive. Similar separation of PRs from IR\/GRs was achieved by IHC and mRNA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-022-01556-6","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T16:08:18Z","timestamp":1662998898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study"],"prefix":"10.1186","volume":"24","author":[{"given":"Elena","family":"Lopez-Knowles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Detre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Hills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene F.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie C. U.","family":"Cheang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Tovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy S.","family":"Kilburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Skene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"1556_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2214-109X(20)30215-1","volume":"8","author":"E Heer","year":"2020","unstructured":"Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8:8.","journal-title":"Lancet Glob Health"},{"key":"1556_CR2","first-page":"10001","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:10001.","journal-title":"Lancet"},{"key":"1556_CR3","first-page":"22","volume":"29","author":"AC Wolff","year":"2011","unstructured":"Wolff AC, Dowsett M. Estrogen receptor: a never ending story? J Clin Oncol. 2011;29:22.","journal-title":"J Clin Oncol"},{"key":"1556_CR4","first-page":"21","volume":"49","author":"JA Foekens","year":"1989","unstructured":"Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, et al. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res. 1989;49:21.","journal-title":"Cancer Res"},{"key":"1556_CR5","first-page":"9793","volume":"378","author":"C Davies","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:9793.","journal-title":"Lancet"},{"key":"1556_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020;144:5.","journal-title":"Arch Pathol Lab Med"},{"key":"1556_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-013-2432-2","volume":"138","author":"X Du","year":"2013","unstructured":"Du X, Li XQ, Li L, Xu YY, Feng YM. The detection of ESR1\/PGR\/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis. Breast Cancer Res Treat. 2013;138:1.","journal-title":"Breast Cancer Res Treat"},{"key":"1556_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s10549-018-4889-5","volume":"172","author":"NC Wu","year":"2018","unstructured":"Wu NC, Wong W, Ho KE, Chu VC, Rizo A, Davenport S, et al. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC\/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform. Breast Cancer Res Treat. 2018;172:2.","journal-title":"Breast Cancer Res Treat"},{"key":"1556_CR9","first-page":"31","volume":"29","author":"C Kim","year":"2011","unstructured":"Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol. 2011;29:31.","journal-title":"J Clin Oncol"},{"issue":"2 Pt","key":"1556_CR10","first-page":"2","volume":"11","author":"M Dowsett","year":"2005","unstructured":"Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005;11(2 Pt):2.","journal-title":"Clin Cancer Res"},{"key":"1556_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020;21:11.","journal-title":"Lancet Oncol"},{"key":"1556_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/npjbcancer.2016.14","volume":"2","author":"SCY Leung","year":"2016","unstructured":"Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016;2:1\u20139.","journal-title":"NPJ Breast Cancer."},{"key":"1556_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/his.13880","volume":"75","author":"SCY Leung","year":"2019","unstructured":"Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, et al. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology. 2019;75:2.","journal-title":"Histopathology"},{"key":"1556_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2559.2006.02513.x","volume":"49","author":"CR Taylor","year":"2006","unstructured":"Taylor CR, Levenson RM. Quantification of immunohistochemistry\u2013issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006;49:4.","journal-title":"Histopathology"},{"key":"1556_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1309\/4WV79N2GHJ3X1841","volume":"123","author":"M Nadji","year":"2005","unstructured":"Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123:1.","journal-title":"Am J Clin Pathol"},{"key":"1556_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12325-019-0896-0","volume":"36","author":"JM Dixon","year":"2019","unstructured":"Dixon JM, Cameron DA, Arthur LM, Axelrod DM, Renshaw L, Thomas JS, et al. Accurate estrogen receptor quantification in patients with negative and low-positive estrogen-receptor-expressing breast tumors: sub-analyses of data from two clinical studies. Adv Ther. 2019;36:4.","journal-title":"Adv Ther"},{"key":"1556_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.7150\/jca.7668","volume":"5","author":"JS Prabhu","year":"2014","unstructured":"Prabhu JS, Korlimarla A, Desai K, Alexander A, Raghavan R, Anupama C, et al. A majority of low (1\u201310%) ER positive breast cancers behave like hormone receptor negative tumors. J Cancer. 2014;5:2.","journal-title":"J Cancer"},{"key":"1556_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2011.36.2574","volume":"30","author":"T Iwamoto","year":"2012","unstructured":"Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012;30:7.","journal-title":"J Clin Oncol"},{"key":"1556_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-14-261","volume":"14","author":"D Hofmann","year":"2013","unstructured":"Hofmann D, Nitz U, Gluz O, Kates RE, Schinkoethe T, Staib P, et al. WSG ADAPT\u2014adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II\/III trial. Trials. 2013;14:1\u201316.","journal-title":"Trials"},{"key":"1556_CR20","first-page":"3","volume":"4","author":"VJ Suman","year":"2015","unstructured":"Suman VJ, Ellis MJ, Ma CX. The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+\/Her2\u2212 invasive breast cancer. Chin Clin Oncol. 2015;4:3.","journal-title":"Chin Clin Oncol"},{"key":"1556_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-021-06148-0","volume":"188","author":"F Fei","year":"2021","unstructured":"Fei F, Siegal GP, Wei S. Characterization of estrogen receptor-low-positive breast cancer. Breast Cancer Res Treat. 2021;188:1.","journal-title":"Breast Cancer Res Treat"},{"key":"1556_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.annonc.2021.08.1988","volume":"32","author":"S Schrodi","year":"2021","unstructured":"Schrodi S, Braun M, Andrulat A, Harbeck N, Mahner S, Kiechle M, et al. Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann Oncol. 2021;32:11.","journal-title":"Ann Oncol"},{"key":"1556_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajcp\/aqy028","volume":"150","author":"A Landmann","year":"2018","unstructured":"Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, et al. Low Estrogen Receptor (ER)-positive breast cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-positive or ER-negative disease? Am J Clin Pathol. 2018;150:1.","journal-title":"Am J Clin Pathol"},{"key":"1556_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1245\/s10434-012-2588-8","volume":"20","author":"B Deyarmin","year":"2013","unstructured":"Deyarmin B, Kane JL, Valente AL, van Laar R, Gallagher C, Shriver CD, et al. Effect of ASCO\/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol. 2013;20:1.","journal-title":"Ann Surg Oncol"},{"key":"1556_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41416-020-1009-1","volume":"123","author":"IK Poon","year":"2020","unstructured":"Poon IK, Tsang JY, Li J, Chan SK, Shea KH, Tse GM. The significance of highlighting the oestrogen receptor low category in breast cancer. Br J Cancer. 2020;123:8.","journal-title":"Br J Cancer"},{"key":"1556_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/annonc\/mdu053","volume":"25","author":"M Yi","year":"2014","unstructured":"Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol. 2014;25:5.","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-022-01556-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-022-01556-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-022-01556-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T04:04:13Z","timestamp":1663041853000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-022-01556-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1186\/s13058-022-01556-6","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"18 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided written informed consent before enrolment. POETIC was approved by the London\u2013South East Research Ethics Committee (reference 08\/H1102\/37).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"M.C.U.C. has a patent for Breast Cancer Classifier: US Patent No. 9,631,239 with royalties paid and receive research funding from NanoString Technologies and veracyte advisory role. MD receives honoraria from Myriad Genetics and is a consultant and advisory board member of GTx, Radius Health, Orion Pharma, Lilly, Agile and Astrazeneca, has received funding from Pfizer (Inst) and Radius Health (Inst) and has been paid expenses from\u00a0Pfizer and Myriad Genetics. JMB reports grants from Cancer Research UK, during the conduct of the study; grants from Medivation; grants and non-financial support from AstraZeneca, Merck Sharp & Dohme, Puma Biotechnology, Clovis Oncology, Pfizer, Janssen-Cilag, Novartis, and Roche, outside the submitted work. LK reports grants from Cancer Research UK, during the conduct of the study. HT received salary from Bayer. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}